Approximately 100,000 people in the U.S. will be diagnosed with melanoma this year, according to the American Cancer Society.

Scientists have pinpointed thousands of genetic changes in a gene that may increase a person's risk of developing breast and ...

The MEDIOLA trial evaluated olaparib (Lynparza) and durvalumab (Imfinzi) with or without bevacizumab in recurrent ovarian cancer and showed a 34% response rate with the PARP inhibitor and the PD-L1 ...

Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free ...

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

If you have any concerns, please consult your physician. Ovarian cancer is the most lethal gynecological malignancy. It is often called a “silent killer” because its symptoms are non-specific ...

Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer who have been treated with three or more prior lines of ...

Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer who have been treated with three or more prior lines of ...

There are currently three types of PARP inhibitors available to women with ovarian cancer, Dr. Janelle Fauci, a gynecologic oncologist with Novant Health in Charlotte, North Carolina, told SurvivorNet ...

Within astrology, Cancer is a water sign represented by the crab. What is the Cancer personality like? Cancers contain multitudes if you're patient enough to let them open up — or if they like ...

A low white blood cell count is called leukopenia. A high white blood cell count is usually a sign of inflammation or infection, but it can be due to a blood-related cancer like leukemia or lymphoma.

NEW YORK – Researchers are planning larger follow-up studies of AstraZeneca's Lynparza (olaparib) in biomarker-selected subgroups after a Phase II trial showed the PARP inhibitor was effective in ...